Audentes Therapeutics (BOLD) Gets a Buy Rating from Mizuho Securities


In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (NASDAQ: BOLD), with a price target of $45. The company’s shares closed yesterday at $33.29.

Yang commented:

“We estimate a total of 21 RMAT designations have been granted by the FDA, including Audentes (see page 2 for a list of all companies that have received the RMAT designation). The list includes a number of gene therapy companies after the FDA expanded the RMAT designation to include gene therapies in November 2017. The RMAT designation for Audentes was granted based on positive results from the ongoing ASPIRO phase 1/2 clinical trial of AT132, illustrated in our latest note (available here).”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 22.4% and a 53.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Revance Therapeutics.

Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $40, representing a 20.2% upside. In a report issued on August 7, William Blair also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $46.18 and a one-year low of $18.44. Currently, Audentes Therapeutics has an average volume of 366.8K.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BOLD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts